메뉴 건너뛰기




Volumn 57, Issue 3, 2012, Pages 592-599

Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma

Author keywords

Erlotinib; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ERLOTINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; VASCULOTROPIN;

EID: 84865107387     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.04.034     Document Type: Article
Times cited : (29)

References (32)
  • 1
    • 1642544603 scopus 로고    scopus 로고
    • Focus on hepatocellular carcinoma
    • DOI 10.1016/S1535-6108(04)00058-3, PII S1535610804000583
    • J. Bruix, L. Boix, M. Sala, and J.M. Llovet Focus on hepatocellular carcinoma Cancer Cell 5 2004 215 219 (Pubitemid 38402113)
    • (2004) Cancer Cell , vol.5 , Issue.3 , pp. 215-219
    • Bruix, J.1    Boix, L.2    Sala, M.3    Llovet, J.M.4
  • 2
    • 83155175343 scopus 로고    scopus 로고
    • Clinical characteristics of patients with hepatocellular carcinoma in Austria - Is there a need for a structured screening program?
    • F. Hucke, W. Sieghart, M. Schöniger-Hekele, M. Peck-Radosavljevic, and C. Müller Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien. Klin. Wochenschr. 123 2011 542 551
    • (2011) Wien. Klin. Wochenschr. , vol.123 , pp. 542-551
    • Hucke, F.1    Sieghart, W.2    Schöniger-Hekele, M.3    Peck-Radosavljevic, M.4    Müller, C.5
  • 3
    • 7044286234 scopus 로고    scopus 로고
    • Introduction: The burden of hepatocellular carcinoma
    • L.B. Seeff Introduction: the burden of hepatocellular carcinoma Gastroenterology 127 2004 S1 S4
    • (2004) Gastroenterology , vol.127
    • Seeff, L.B.1
  • 4
    • 55749088393 scopus 로고    scopus 로고
    • Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    • S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
    • (2008) Mol Cancer Ther , vol.7 , pp. 3129-3140
    • Wilhelm, S.M.1    Adnane, L.2    Newell, P.3    Villanueva, A.4    Llovet, J.M.5    Lynch, M.6
  • 5
    • 33846212284 scopus 로고    scopus 로고
    • Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    • DOI 10.1158/0008-5472.CAN-06-1377
    • L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858 (Pubitemid 46094197)
    • (2006) Cancer Research , vol.66 , Issue.24 , pp. 11851-11858
    • Liu, L.1    Cao, Y.2    Chen, C.3    Zhang, X.4    McNabola, A.5    Wilkie, D.6    Wilhelm, S.7    Lynch, M.8    Carter, C.9
  • 7
    • 33846625146 scopus 로고    scopus 로고
    • COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival
    • DOI 10.1245/s10434-006-9123-8
    • J. Foster, J. Black, C. LeVea, T. Khoury, B. Kuvshinoff, and M. Javle COX-2 Expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival Ann Surg Oncol 14 2007 752 758 (Pubitemid 46175323)
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.2 , pp. 752-758
    • Foster, J.1    Black, J.2    LeVea, C.3    Khoury, T.4    Kuvshinoff, B.5    Javle, M.6    Gibbs, J.F.7
  • 8
    • 40449113855 scopus 로고    scopus 로고
    • Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma
    • DOI 10.1309/WF10QAAED3PP93BH
    • A.F. Buckley, L.J. Burgart, V. Sahai, and S. Kakar Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma Am J Clin Pathol 129 2008 245 251 (Pubitemid 352029315)
    • (2008) American Journal of Clinical Pathology , vol.129 , Issue.2 , pp. 245-251
    • Buckley, A.F.1    Burgart, L.J.2    Sahai, V.3    Kakar, S.4
  • 9
    • 38049059334 scopus 로고    scopus 로고
    • Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis
    • K.K. Tanabe, A. Lemoine, D.M. Finkelstein, H. Kawasaki, T. Fujii, and R.T. Chung Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis JAMA 299 2008 53 60
    • (2008) JAMA , vol.299 , pp. 53-60
    • Tanabe, K.K.1    Lemoine, A.2    Finkelstein, D.M.3    Kawasaki, H.4    Fujii, T.5    Chung, R.T.6
  • 10
    • 33748627437 scopus 로고    scopus 로고
    • Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: Implications for angiogenesis
    • M. Woo Sung, P. Ho Sung, Y. Ki Hoon, P. MinYoung, K. Kyung Ryoul, and J. Kyu Yun Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis Hum Pathol 37 2006 1324 1332
    • (2006) Hum Pathol , vol.37 , pp. 1324-1332
    • Woo Sung, M.1    Ho Sung, P.2    Ki Hoon, Y.3    Minyoung, P.4    Kyung Ryoul, K.5    Kyu Yun, J.6
  • 11
    • 40849147041 scopus 로고    scopus 로고
    • EGFR antagonists in cancer treatment
    • F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
    • (2008) N Engl J Med , vol.358 , pp. 1160-1174
    • Ciardiello, F.1    Tortora, G.2
  • 12
    • 24344489502 scopus 로고    scopus 로고
    • Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics
    • DOI 10.1016/j.jhep.2005.02.040, PII S0168827805002771
    • A. Huether, M. Hopfner, A.P. Sutter, D. Schuppan, and H. Scherubl Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics J Hepatol 43 2005 661 669 (Pubitemid 41253234)
    • (2005) Journal of Hepatology , vol.43 , Issue.4 , pp. 661-669
    • Huether, A.1    Hopfner, M.2    Sutter, A.P.3    Schuppan, D.4    Scherubl, H.5
  • 15
  • 17
    • 11244302427 scopus 로고    scopus 로고
    • Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells
    • DOI 10.1096/fj.04-2111fje
    • D. Jurek, N. Udilova, A. Jozkowicz, H. Nohl, B. Marian, and R. Schulte-Hermann Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells FASEB J 19 2005 97 99 (Pubitemid 40069930)
    • (2005) FASEB Journal , vol.19 , Issue.1 , pp. 97-99
    • Jurek, D.1    Udilova, N.2    Jozkowicz, A.3    Nohl, H.4    Marian, B.5    Schulte-Hermann, R.6
  • 20
    • 77949322163 scopus 로고    scopus 로고
    • Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab
    • G.W. Prager, E.-M. Lackner, M.-T. Krauth, M. Unseld, M. Poettler, and S. Laffer Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab Mol Oncol 4 2010 150 160
    • (2010) Mol Oncol , vol.4 , pp. 150-160
    • Prager, G.W.1    Lackner, E.-M.2    Krauth, M.-T.3    Unseld, M.4    Poettler, M.5    Laffer, S.6
  • 21
    • 44649105082 scopus 로고    scopus 로고
    • Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
    • A.-C. Piguet, D. Semela, A. Keogh, L. Wilkens, D. Stroka, and C. Stoupis Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma J Hepatol 49 2008 78 87
    • (2008) J Hepatol , vol.49 , pp. 78-87
    • Piguet, A.-C.1    Semela, D.2    Keogh, A.3    Wilkens, L.4    Stroka, D.5    Stoupis, C.6
  • 22
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
    • A.-L. Cheng, Y.-K. Kang, Z. Chen, C.-J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.-L.1    Kang, Y.-K.2    Chen, Z.3    Tsao, C.-J.4    Qin, S.5    Kim, J.S.6
  • 25
    • 74249092481 scopus 로고    scopus 로고
    • Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
    • N. Murukesh, C. Dive, and G.C. Jayson Biomarkers of angiogenesis and their role in the development of VEGF inhibitors Br J Cancer 102 2009 8 18
    • (2009) Br J Cancer , vol.102 , pp. 8-18
    • Murukesh, N.1    Dive, C.2    Jayson, G.C.3
  • 26
    • 46449091500 scopus 로고    scopus 로고
    • Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
    • A.B. Siegel, E.I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, and J.J. Knox Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992 2998
    • (2008) J Clin Oncol , vol.26 , pp. 2992-2998
    • Siegel, A.B.1    Cohen, E.I.2    Ocean, A.3    Lehrer, D.4    Goldenberg, A.5    Knox, J.J.6
  • 27
    • 0035132143 scopus 로고    scopus 로고
    • Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study
    • DOI 10.1097/00000658-200102000-00012
    • R.T.-P. Poon, I.O.-L. Ng, C. Lau, L.-X. Zhu, W.-C. Yu, and C.-M. Lo Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study Ann Surg 233 2001 227 235 (Pubitemid 32106077)
    • (2001) Annals of Surgery , vol.233 , Issue.2 , pp. 227-235
    • Poon, R.T.-P.1    Ng, I.O.-L.2    Lau, C.3    Zhu, L.-X.4    Yu, W.-C.5    Lo, C.-M.6    Fan, S.-T.7    Wong, J.8
  • 28
    • 34249900712 scopus 로고    scopus 로고
    • High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
    • DOI 10.1245/s10434-007-9366-z
    • R. Poon, C. Lau, R. Pang, K. Ng, J. Yuen, and S. Fan High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies Ann Surg Oncol 14 2007 1835 1845 (Pubitemid 46870942)
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.6 , pp. 1835-1845
    • Poon, R.T.P.1    Lau, C.2    Pang, R.3    Ng, K.K.4    Yuen, J.5    Fan, S.T.6
  • 29
    • 4644289324 scopus 로고    scopus 로고
    • Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level
    • X. Li, G.S. Feng, C.S. Zheng, C.K. Zhuo, and X. Liu Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level World J Gastroenterol 10 2004 2878 2882 (Pubitemid 39303010)
    • (2004) World Journal of Gastroenterology , vol.10 , Issue.19 , pp. 2878-2882
    • Li, X.1    Feng, G.-S.2    Zheng, C.-S.3    Zhuo, C.-K.4    Liu, X.5
  • 31
    • 0141679409 scopus 로고    scopus 로고
    • Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma
    • G. Giannelli, E. Fransvea, C. Bergamini, F. Marinosci, and S. Antonaci Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma Clin Cancer Res 9 2003 3684 3691 (Pubitemid 37169236)
    • (2003) Clinical Cancer Research , vol.9 , Issue.10 , pp. 3684-3691
    • Giannelli, G.1    Fransvea, E.2    Bergamini, C.3    Marinosci, F.4    Antonaci, S.5
  • 32
    • 11244275453 scopus 로고    scopus 로고
    • Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells
    • DOI 10.1038/sj.bjc.6602231
    • G. Giannelli, A. Azzariti, E. Fransvea, L. Porcelli, S. Antonaci, and A. Paradiso Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells Br J Cancer 91 2004 1964 1969 (Pubitemid 40065526)
    • (2004) British Journal of Cancer , vol.91 , Issue.11 , pp. 1964-1969
    • Giannelli, G.1    Azzariti, A.2    Fransvea, E.3    Porcelli, L.4    Antonaci, S.5    Paradiso, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.